Evidence map›Paper›PMID 31851428›Full record

ArticleThoracic cancer2020

Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study.

Shinnosuke Takemoto, Minoru Fukuda, Hiroyuki Yamaguchi, Takaya Ikeda, Kazumasa Akagi, Hiromi Tomono, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyotoku and 8 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Malignant pleural disease.Breathe (Sheffield, England) · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Shinnosuke TakemotoDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0003-0373-0618
Minoru FukudaDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0002-5321-1843
Hiroyuki YamaguchiDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0002-9182-5694
Takaya IkedaDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Kazumasa AkagiDepartment of Respiratory Medicine, Nagasaki Prefecture Shimabara Hospital, Shimabara, Japan.
Hiromi TomonoDepartment of Respiratory Medicine, Sasebo City General Hospital, Sasebo, Japan.
Yasuhiro UmeyamaDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Yosuke DotsuDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hirokazu TaniguchiDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0003-2414-8344
Hiroshi GyotokuDepartment of Respiratory Medicine, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan.
Hiroaki SenjuDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Takeshi KitazakiDivision of Respiratory Diseases, Department of Internal Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Katsumi NakatomiDepartment of Respiratory Medicine, National Hospital Organization Ureshino Medical Center, Ureshino, Japan.
Seiji NagashimaDepartment of Respiratory Medicine, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan.
Masaaki FukudaDivision of Respiratory Diseases, Department of Internal Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Akitoshi KinoshitaDepartment of Respiratory Medicine, Nagasaki Prefecture Shimabara Hospital, Shimabara, Japan.
Hiroshi SodaDepartment of Respiratory Medicine, Sasebo City General Hospital, Sasebo, Japan.ORCID 0000-0003-4993-1837
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Japanese Red Cross Society, Japan · JPNagasaki University · JPNagasaki Medical Center · JPNagasaki Prefectural Shimabara High School · JPSasebo City General Hospital · JPNational Cancer Center Hospital East · JP

Funding

Eli Lilly Company
6 · The paper itself

Abstract

introductionAnti-vascular endothelial growth factor therapy has been shown to be effective in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE); however, there are no data to suggest that ramucirumab has the same effects.

methodsWe therefore decided to conduct a phase II study of ramucirumab plus docetaxel for NSCLC patients with MPE. The MPE control rate at eight weeks after the start of treatment will be the primary endpoint, and the objective response rate, progression-free survival, one-year survival rate, overall survival, and toxicity profile will be secondary endpoints. DISCUSSION: A previous study indicated that administering chemotherapy in combination with bevacizumab was effective at controlling pleural effusion in patients with NSCLC with carcinomatous pleurisy. It is expected that ramucirumab will have a similar effect to the same group.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungClinical Trials, Phase II as TopicDocetaxelFollow-Up StudiesHumansLung NeoplasmsMulticenter Studies as TopicPleural Effusion, MalignantPrognosisRamucirumabSalvage TherapySurvival RateAntibodies, Monoclonal, HumanizedDocetaxelRamucirumabdocetaxelNSCLCpleural effusionramucirumab

Identifiers

PMID31851428
PMCPMC6996979
OpenAlexW2994623283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.